UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antigen Specificity Enhances Disease Control by Tregs in Vitiligo

Frontiers in immunology, 2020-12, Vol.11, p.581433-581433

2020

Volltextzugriff (PDF)

YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells

iScience, 2018-04, Vol.2, p.105-122

2018

Volltextzugriff (PDF)

The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective

Cancer gene therapy, 2017-03, Vol.24 (3), p.89-99

Junghans, Richard P

2017

Volltextzugriff (PDF)

STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells

Oncogene, 2019-01, Vol.38 (4), p.533-548

2019

Volltextzugriff (PDF)

Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils

Journal of leukocyte biology, 2013-10, Vol.94 (4), p.813-823

2013

Volltextzugriff (PDF)

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

Clinical cancer research, 2015-07, Vol.21 (14), p.3149-3159

2015

Volltextzugriff (PDF)

Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation

Clinical cancer research, 2008-12, Vol.14 (24), p.8112-8122

2008

Volltextzugriff (PDF)

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

The Prostate, 2016-10, Vol.76 (14), p.1257-1270

2016

Volltextzugriff (PDF)

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

Cancer Immunology, Immunotherapy, 2015-07, Vol.64 (7), p.817-829

2015

Volltextzugriff (PDF)

The emerging role of protein kinase Cθ in cytoskeletal signaling

Journal of leukocyte biology, 2013-03, Vol.93 (3), p.319-327

2013

Volltextzugriff (PDF)

HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases

Cancer gene therapy, 2020-05, Vol.27 (5), p.341-355

2020

Volltextzugriff (PDF)

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience

Molecular therapy. Methods & clinical development, 2018-09, Vol.10, p.371-378

2018

Volltextzugriff (PDF)

T cell exhaustion and Interleukin 2 downregulation

Cytokine (Philadelphia, Pa.), 2015-02, Vol.71 (2), p.339-347

2015

Volltextzugriff (PDF)

Engineering Axl specific CAR and SynNotch receptor for cancer therapy

Scientific reports, 2018-03, Vol.8 (1), p.3846-3846, Article 3846

2018

Volltextzugriff (PDF)

Frontline Science: Functionally impaired geriatric CAR‐T cells rescued by increased α5β1 integrin expression

Journal of leukocyte biology, 2017-08, Vol.102 (2), p.201-208

2017

Volltextzugriff (PDF)

Autoimmunity associated with immunotherapy of cancer

Blood, 2011-07, Vol.118 (3), p.499-509

2011

Volltextzugriff (PDF)

Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells

Virology (New York, N.Y.), 2013-11, Vol.446 (1), p.268-275

2013

Volltextzugriff (PDF)

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

Proceedings of the National Academy of Sciences - PNAS, 2015-10, Vol.112 (42), p.13045-13050

2015

Volltextzugriff (PDF)

Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor― Modified T Cells

Clinical cancer research, 2012-11, Vol.18 (21), p.5949-5960

2012

Volltextzugriff (PDF)

HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery

Journal for immunotherapy of cancer, 2020-08, Vol.8 (2), p.e001097

2020

Volltextzugriff (PDF)

Advanced generation anti-prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy

The Prostate, 2014-02, Vol.74 (3), p.286-296

2014

Volltextzugriff (PDF)

Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor ζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors

Clinical cancer research, 2010-05, Vol.16 (10), p.2769-2780

2010

Volltextzugriff (PDF)

Is It Safer CARs That We Need, or Safer Rules of the Road?

Molecular therapy, 2010-10, Vol.18 (10), p.1742-1743

Junghans, Richard P

2010

Volltextzugriff (PDF)

Author Correction: Engineering Axl specific CAR and SynNotch receptor for cancer therapy

Scientific reports, 2020-02, Vol.10 (1), p.3000-3000, Article 3000

2020

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(78)

Publikationsform

Artikel
(83)

Sprache

Englisch
(83)

Erscheinungsjahr

n.n

Thema

Science & Technology
(50)
Life Sciences & Biomedicine
(46)
Humans
(44)
Animals
(28)
Mice
(21)
Male
(17)
Immunotherapy
(16)
Immunology
(15)
Medicine, Research & Experimental
(15)
Oncology
(15)
Research & Experimental Medicine
(15)
Antigens
(14)
T-Lymphocytes - Immunology
(14)
Biological And Medical Sciences
(13)
Female
(13)
Gene Therapy
(12)
Receptors, Antigen, T-Cell - Immunology
(12)
Immunotherapy, Adoptive - Methods
(11)
Medical Sciences
(11)
Receptors, Antigen, T-Cell - Genetics
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Antigen Specificity Enhances Disease Control by Tregs in Vitiligo

YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells

The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective

STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells

Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

The emerging role of protein kinase Cθ in cytoskeletal signaling

HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience

Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice

T cell exhaustion and Interleukin 2 downregulation

Engineering Axl specific CAR and SynNotch receptor for cancer therapy

Frontline Science: Functionally impaired geriatric CAR‐T cells rescued by increased α5β1 integrin expression

Autoimmunity associated with immunotherapy of cancer

Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor― Modified T Cells

HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery

Advanced generation anti-prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy

Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor ζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors

Is It Safer CARs That We Need, or Safer Rules of the Road?

Author Correction: Engineering Axl specific CAR and SynNotch receptor for cancer therapy

Suchergebnisse filtern